Radiotheranostics in oncology: making precision medicine possible
EO Aboagye, TD Barwick… - CA: a cancer journal for …, 2023 - Wiley Online Library
A quintessential setting for precision medicine, theranostics refers to a rapidly evolving field
of medicine in which disease is diagnosed followed by treatment of disease‐positive …
of medicine in which disease is diagnosed followed by treatment of disease‐positive …
Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?
N Lepareur - Frontiers in Medicine, 2022 - frontiersin.org
Over the last couple of decades, gallium-68 (68Ga) has gained a formidable interest for PET
molecular imaging of various conditions, from cancer to infection, through cardiac …
molecular imaging of various conditions, from cancer to infection, through cardiac …
Imaging of CXC motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-pentixafor PET
In recent years, molecular imaging addressing the CXC motif chemokine receptor 4
(CXCR4) has increasingly been used in various clinical settings. Here, we aimed to assess …
(CXCR4) has increasingly been used in various clinical settings. Here, we aimed to assess …
CXCR4-targeted theranostics in oncology
A growing body of literature reports on the upregulation of CXC motif chemokine receptor 4
(CXCR4) in a variety of cancer entities, rendering this receptor as suitable target for …
(CXCR4) in a variety of cancer entities, rendering this receptor as suitable target for …
Clinical advances and perspectives in targeted radionuclide therapy
N Lepareur, B Ramée, M Mougin-Degraef… - Pharmaceutics, 2023 - mdpi.com
Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine
subspecialty. For many decades, treatment with radionuclides has been mainly restricted to …
subspecialty. For many decades, treatment with radionuclides has been mainly restricted to …
In vivo targeting of CXCR4—new horizons
M Schottelius, K Herrmann, C Lapa - Cancers, 2021 - mdpi.com
Simple Summary Beyond its pre-eminent role in the context of tumor cell growth as well as
metastasis, the CXC motif chemokine receptor 4 (CXCR4) is a key player in the …
metastasis, the CXC motif chemokine receptor 4 (CXCR4) is a key player in the …
[HTML][HTML] A new class of PentixaFor-and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency
T Osl, A Schmidt, M Schwaiger, M Schottelius… - Theranostics, 2020 - ncbi.nlm.nih.gov
Non-invasive PET imaging of CXCR4 expression in cancer and inflammation as well as
CXCR4-targeted radioligand therapy (RLT) have recently found their way into clinical …
CXCR4-targeted radioligand therapy (RLT) have recently found their way into clinical …
Advances in PET imaging of the CXCR4 receptor:[68Ga] Ga-PentixaFor
L Lindenberg, M Ahlman, F Lin, E Mena… - Seminars in Nuclear …, 2024 - Elsevier
Highlights•[68 Ga] Ga-PentixaFor is a new molecular imaging agent targeting the CXC motif
chemokine ligand 12 (CXCL12)-Chemokine receptor-4 (CXCR4) chemokine axis.•CXCR4 is …
chemokine ligand 12 (CXCL12)-Chemokine receptor-4 (CXCR4) chemokine axis.•CXCR4 is …
Radiolabelled peptides for positron emission tomography and endoradiotherapy in oncology
C Rangger, R Haubner - Pharmaceuticals, 2020 - mdpi.com
This review deals with the development of peptide-based radiopharmaceuticals for the use
with positron emission tomography and peptide receptor radiotherapy. It discusses the pros …
with positron emission tomography and peptide receptor radiotherapy. It discusses the pros …
CXCR4-directed PET/CT in patients with newly diagnosed neuroendocrine carcinomas
We aimed to elucidate the diagnostic potential of the CXC motif chemokine receptor 4
(CXCR4)-directed positron emission tomography (PET) tracer 68Ga-Pentixafor in patients …
(CXCR4)-directed positron emission tomography (PET) tracer 68Ga-Pentixafor in patients …